Oral decitabine plus ivosidenib first line AML trial

ClinicalTrials.gov recorded a new clinical trial registration (NCT07507760) for a study evaluating oral decitabine combined with ivosidenib for first-line treatment of acute myeloid leukemia. The registration provides the study title and NCT identifier as the primary metadata. This is a standard clinical trial registration entry with no new regulatory requirements or policy changes.

No immediate compliance actions are required. Healthcare providers, clinical investigators, and patients interested in AML treatment options may reference this trial for enrollment eligibility and study design information. The registration is informational and does not impose any deadlines, penalties, or mandatory reporting obligations on regulated entities.